A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis

Rinako Yasuda, Katsuhiko Naoki, Hiroaki Okamoto, Shuko Tsujimura, Tomoki Fujii, Naoya Hida, Hiroshi Kunikane, Kenzo Soejima, Akitoshi Ishizaka, Koshiro Watanabe

Research output: Contribution to journalArticle

Abstract

In recent years there are many patients who undergo hemodialysis because of chronic renal failure. Along with that, cases where lung cancer is discovered in patients undergoing hemodialysis are increasing. However, a standard chemotherapy for lung cancer patients undergoing maintenance hemodialysis has not yet been established with this in mind, we conducted chemotherapy using carboplatin 300mg/m 2(day 1) plus etoposide 50mg/m 2(day 1, 3) in a patient with limited-stage small cell lung cancer, who was also receiving maintenance hemodialysis. We investigated 16 small-cell lung cancer cases reported since 2000 in Japan that had been treated with carboplatin and etoposide under hemodialysis for chronic renal failure. Reviewing these cases, it is suggested that most effective schedule would be to use a higher dose in the first course followed by dose reduction as necessary for further courses. Although we were able to treat this case safely, the response was limited to an SD(stable disease). Further study is needed to determine the optimal dosage of each drug for small-cell lung cancer with maintenance hemodialysis.

Original languageEnglish
Pages (from-to)963-968
Number of pages6
JournalRespiration and Circulation
Volume57
Issue number9
Publication statusPublished - 2009 Sep

Fingerprint

Carboplatin
Small Cell Lung Carcinoma
Etoposide
Combination Drug Therapy
Renal Dialysis
Maintenance
Chronic Kidney Failure
Lung Neoplasms
Drug Therapy
Appointments and Schedules
Japan
Pharmaceutical Preparations

Keywords

  • Combined chemotherapy
  • Hemodialysis
  • Small cell lung cancer

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Yasuda, R., Naoki, K., Okamoto, H., Tsujimura, S., Fujii, T., Hida, N., ... Watanabe, K. (2009). A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis. Respiration and Circulation, 57(9), 963-968.

A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis. / Yasuda, Rinako; Naoki, Katsuhiko; Okamoto, Hiroaki; Tsujimura, Shuko; Fujii, Tomoki; Hida, Naoya; Kunikane, Hiroshi; Soejima, Kenzo; Ishizaka, Akitoshi; Watanabe, Koshiro.

In: Respiration and Circulation, Vol. 57, No. 9, 09.2009, p. 963-968.

Research output: Contribution to journalArticle

Yasuda, R, Naoki, K, Okamoto, H, Tsujimura, S, Fujii, T, Hida, N, Kunikane, H, Soejima, K, Ishizaka, A & Watanabe, K 2009, 'A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis', Respiration and Circulation, vol. 57, no. 9, pp. 963-968.
Yasuda, Rinako ; Naoki, Katsuhiko ; Okamoto, Hiroaki ; Tsujimura, Shuko ; Fujii, Tomoki ; Hida, Naoya ; Kunikane, Hiroshi ; Soejima, Kenzo ; Ishizaka, Akitoshi ; Watanabe, Koshiro. / A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis. In: Respiration and Circulation. 2009 ; Vol. 57, No. 9. pp. 963-968.
@article{88b16684146f4e2bb0d9faa2d14be4ec,
title = "A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis",
abstract = "In recent years there are many patients who undergo hemodialysis because of chronic renal failure. Along with that, cases where lung cancer is discovered in patients undergoing hemodialysis are increasing. However, a standard chemotherapy for lung cancer patients undergoing maintenance hemodialysis has not yet been established with this in mind, we conducted chemotherapy using carboplatin 300mg/m 2(day 1) plus etoposide 50mg/m 2(day 1, 3) in a patient with limited-stage small cell lung cancer, who was also receiving maintenance hemodialysis. We investigated 16 small-cell lung cancer cases reported since 2000 in Japan that had been treated with carboplatin and etoposide under hemodialysis for chronic renal failure. Reviewing these cases, it is suggested that most effective schedule would be to use a higher dose in the first course followed by dose reduction as necessary for further courses. Although we were able to treat this case safely, the response was limited to an SD(stable disease). Further study is needed to determine the optimal dosage of each drug for small-cell lung cancer with maintenance hemodialysis.",
keywords = "Combined chemotherapy, Hemodialysis, Small cell lung cancer",
author = "Rinako Yasuda and Katsuhiko Naoki and Hiroaki Okamoto and Shuko Tsujimura and Tomoki Fujii and Naoya Hida and Hiroshi Kunikane and Kenzo Soejima and Akitoshi Ishizaka and Koshiro Watanabe",
year = "2009",
month = "9",
language = "English",
volume = "57",
pages = "963--968",
journal = "Respiration and Circulation",
issn = "0452-3458",
publisher = "Igaku-Shoin Ltd",
number = "9",

}

TY - JOUR

T1 - A case of small-cell lung carcinoma treated with carboplatin plus etoposide combination chemotherapy under hemodialysis

AU - Yasuda, Rinako

AU - Naoki, Katsuhiko

AU - Okamoto, Hiroaki

AU - Tsujimura, Shuko

AU - Fujii, Tomoki

AU - Hida, Naoya

AU - Kunikane, Hiroshi

AU - Soejima, Kenzo

AU - Ishizaka, Akitoshi

AU - Watanabe, Koshiro

PY - 2009/9

Y1 - 2009/9

N2 - In recent years there are many patients who undergo hemodialysis because of chronic renal failure. Along with that, cases where lung cancer is discovered in patients undergoing hemodialysis are increasing. However, a standard chemotherapy for lung cancer patients undergoing maintenance hemodialysis has not yet been established with this in mind, we conducted chemotherapy using carboplatin 300mg/m 2(day 1) plus etoposide 50mg/m 2(day 1, 3) in a patient with limited-stage small cell lung cancer, who was also receiving maintenance hemodialysis. We investigated 16 small-cell lung cancer cases reported since 2000 in Japan that had been treated with carboplatin and etoposide under hemodialysis for chronic renal failure. Reviewing these cases, it is suggested that most effective schedule would be to use a higher dose in the first course followed by dose reduction as necessary for further courses. Although we were able to treat this case safely, the response was limited to an SD(stable disease). Further study is needed to determine the optimal dosage of each drug for small-cell lung cancer with maintenance hemodialysis.

AB - In recent years there are many patients who undergo hemodialysis because of chronic renal failure. Along with that, cases where lung cancer is discovered in patients undergoing hemodialysis are increasing. However, a standard chemotherapy for lung cancer patients undergoing maintenance hemodialysis has not yet been established with this in mind, we conducted chemotherapy using carboplatin 300mg/m 2(day 1) plus etoposide 50mg/m 2(day 1, 3) in a patient with limited-stage small cell lung cancer, who was also receiving maintenance hemodialysis. We investigated 16 small-cell lung cancer cases reported since 2000 in Japan that had been treated with carboplatin and etoposide under hemodialysis for chronic renal failure. Reviewing these cases, it is suggested that most effective schedule would be to use a higher dose in the first course followed by dose reduction as necessary for further courses. Although we were able to treat this case safely, the response was limited to an SD(stable disease). Further study is needed to determine the optimal dosage of each drug for small-cell lung cancer with maintenance hemodialysis.

KW - Combined chemotherapy

KW - Hemodialysis

KW - Small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=70350062205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350062205&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 963

EP - 968

JO - Respiration and Circulation

JF - Respiration and Circulation

SN - 0452-3458

IS - 9

ER -